Conference Correspondent

Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health. Read More ›

Researchers presented 2-year follow-up safety and efficacy results of a phase 2 open-label study that compared the efficacy and safety of combination therapy with the anti-SLAM7 monoclonal antibody elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Researchers presented updated safety and efficacy results of a 2-part study (GEN503) that evaluated combination therapy with the anti-CD38 monoclonal antibody daratumumab plus lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM). Read More ›

Researchers reported results of a global, multicenter, retrospective International Myeloma Working Group study that assessed the current treatment approaches utilized for initial treatment after first relapse and salvage treatment of patients with multiple myeloma (MM), and examined patient outcomes following successive therapies with the goal of examining the natural history of relapsed MM. Read More ›

Researchers presented results of the randomized, placebo-controlled phase 3 Tourmaline-MM1 study that evaluated the benefit of adding the oral proteasome inhibitor ixazomib to the lenalidomide and dexamethasone (Rd) backbone compared with placebo plus Rd in patients with relapsed and/or refractory multiple myeloma (RRMM). Read More ›

Researchers reported on a study that assessed the clinical utility of minimal residual disease (MRD) monitoring in elderly patients with multiple myeloma (MM) included in the PETHEMA/GEM2010MAS65 trial. Read More ›